Avidity Biosciences

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avidity Biosciences (NASDAQ: RNA ) stock is soaring in early trading after the company disclosed that it had expanded its partnership with a huge drugmaker, Bristol Myers Squibb (NYSE: BMY ). More About the RNA-BMY Deal Avidity and Bristol-Myers will increase the number of Antibody Oligonucleotide Conjugates (AOCs) on which they will collaborate in an effort to develop new cardiovascular treatments.

Why Is Avidity Biosciences (RNA) Stock Up 15% Today?

Bristol-Myers

Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.

Avidity Stock Soars on Collaboration Deal With Bristol Myers

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY).  The pact is focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potential to earn up to $2.2 billion in milestone payments. The news sent Avidity's stock up 21% in premarket trade.

Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity reported new positive AOC 1001 data at World Muscle Society (WMS) Congress in October demonstrating consistent improvement in multiple additional functional endpoints and favorable long-term safety and tolerability in people living with myotonic dystrophy type 1 (DM1) AOC 1044 receives Orphan Designation for the treatment of DMD in US and EU Avidity remains on track to report data readouts from three clinical development programs – DM1, DMD and FSHD – over the next nine months SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the third quarter ended September 30, 2023. Avidity ended the third quarter of 2023 with cash, cash equivalents and marketable securities totaling $542.6 million.

Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights

SAN DIEGO , Sept. 26, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and six poster presentations at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023, in Charleston, South Carolina.

Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity joins with MDF community leaders, patients, caregivers, and legislators in educational briefing to highlight the latest scientific advancements in myotonic dystrophy research and development Company advancing clinical development programs for three types of muscular dystrophy – DM1, DMD and FSHD – with planned data readouts over the next 12 months SAN DIEGO , Sept. 7, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases.

Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs

SAN DIEGO , Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two poster presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, being held September 7-9, 2023, in Washington, D.C. POSTER PRESENTATIONS September 9, 2023: 12:30 p.m.

Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.92 per share a year ago.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

Advancing three clinical development programs – DM1, DMD, FSHD - with data anticipated from each program over the next 12 months SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results and recent highlights for the second quarter ended June 30, 2023. Avidity ended the second quarter of 2023 with cash, cash equivalents and marketable securities totaling $577 million.

Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights

Avidity Biosciences, Inc. stock is down significantly since my last article. The company, despite some early setback, is doing promising science. They have enough cash to execute their lead program.

Avidity Biosciences: Large Devaluation Of Stock Presents Opportunity

Avidity is currently enrolling participants in the Phase 1/2 FORTITUDE™ study of AOC 1020 for the treatment of FSHD Company anticipates data from a preliminary assessment in half of the participants in the FORTITUDE study in 1H 2024 SAN DIEGO , June 20, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), joins with the global community of patients, caregivers, and healthcare providers in support of World Facioscapulohumeral Muscular Dystrophy (FSHD) Day. FSHD is a serious, rare, hereditary muscle-weakening condition marked by life-long, progressive loss of muscle function that causes significant pain, fatigue, and disability.

Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day

SAN DIEGO , June 8, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two oral presentations and two poster presentations at the 30th Annual FSHD Society International Research Congress, being held June 15-16, 2023, in Milan, Italy. ORAL PRESENTATIONS June 15, 2023: 5:10 p.m.

Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.71 per share a year ago.

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates

Positive topline data from AOC 1001 Phase 1/2 MARINA™ trial demonstrated functional improvement, disease modification and favorable safety and tolerability profile in people living with myotonic dystrophy type 1 Advancing three programs in clinical trials with data expected later this year - first look at data from open-label extension study, MARINA-OLE™; healthy volunteer data from EXPLORE44™ Expands research and development pipeline with rare skeletal muscle and first cardiology programs SAN DIEGO , May 9, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the first quarter ended March 31, 2023 and highlighted recent corporate progress. Avidity ended the first quarter of 2023 with cash, cash equivalents and marketable securities totaling $586.3 million.

Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

SAN DIEGO, April 27, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1) demonstrating functional improvement, DMPK reduction, splicing improvements and a favorable safety and tolerability profile. The AOC 1001 topline data were highlighted in an oral presentation at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston, Mass. AOC 1001, Avidity's lead clinical program utilizing its AOC platform, is designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies.

Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA™ Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1

Avidity Biosciences: An Interesting Diversification.

Avidity Biosciences: An Interesting Diversification

NEW YORK , April 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA

SAN DIEGO, April 17, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced presentations at the 75th American Academy of Neurology (AAN) Annual Meeting, including an oral presentation on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2 MARINA™ trial. The 75th AAN Annual Meeting is taking place in Boston, Mass., April 22-27, 2023.

Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting

Avidity Biosciences updated investors about a problem in one of its clinical trials. A patient had serious side effects that are quite rare.

After Falling 18% in 1 Day, Is This Growth Stock Done For?

Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.

Avidity (RNA) Down on Update From Neuromuscular Disease Study

A key study from Avidity Biosciences remains on hold after a patient experienced a rare side effect, leading RNA stock to plummet Thursday. The post Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study appeared first on Investor's Business Daily.

Avidity Bio Crashes 26% After 'Rarer Than Rare' Event Sidelines Key Study

Shares of Avidity Biosciences Inc. RNA, +0.55% fell about 3.0% in premarket trading on Thursday after the company said a partial clinical hold on its experimental treatment for adults with myotonic dystrophy type 1 is still in place. The Food and Drug Administration placed the partial clinical hold on enrolling new patients in the Phase 1/2 clinical trial in September after a serious adverse event was reported.

Avidity's stock falls after sharing additional data about partial clinical hold

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting two oral presentations and multiple poster presentations at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, being held March 19-22, 2023. ORAL PRESENTATIONS      March 22, 2023: 10:30 a.m.

Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference

Avidity Biosciences, Inc. is a leader in antibody Oligonucleotide conjugate technology. This technology enables delivery of Oligonucleotides to muscles and other tissues.

News for Avidity Biosciences Stock (RNA)